Injury & recovery
BPC-157 vs TB-500
Both are discussed for recovery, but BPC-157 has a larger preclinical literature while TB-500 fragment has even less direct human drug-exposure evidence..
At a glance
BPC-157
TB-500
Human evidence
Human evidence remains extremely limited. A 2025 systematic review found 35 preclinical studies and only one clinical study; a later retrospective real-world preprint cannot establish efficacy. GI and injury-healing claims remain dominated by animal/preclinical research.
No verified human drug-product exposure or therapeutic outcome dataset for the TB-500 fragment was identified. A 2026 rat Achilles-tendon study provides direct preclinical evidence for the fragment. A ClinicalTrials.gov-style TB-500 record encountered during research explicitly states that it is fictional/example content and is not counted.
Research focus
Musculoskeletal injury, gastrointestinal and wound-healing research
Wound/tissue-repair research claims
Regulatory status
Not FDA-approved; FDA has highlighted safety-information gaps for compounded BPC-157.
Not FDA-approved; FDA has reviewed TB-500-related substances in the compounding context and highlights safety/data gaps.
Route / formulation
Results from animal models cannot be presented as proven human healing effects. Research-grade product quality varies.
TB-500 fragment evidence must remain separate from full-length thymosin beta-4 and from fictional/example registry content.
No direct head-to-head human efficacy trial identified Both are discussed for recovery, but BPC-157 has a larger preclinical literature while TB-500 fragment has even less direct human drug-exposure evidence. Neither has established routine human efficacy for musculoskeletal injury.